Page 134 - 南京医科大学自然版

第45卷第7期
·1032 · 南 京 医 科 大 学 学 报 2025年7月

Multiple Myeloma Expert Committee of Chinese Society ［26］LONG N M，SMITH C S. Causes and imaging features of
of Clinical Oncology（CSCO），Myeloma & Plasma Cell false positives and false negatives on F⁃PET/CT in onco⁃
Disease Group，Hematology Oncology Committee of Chi⁃ logic imaging［J］. Insights Imaging，2011，2（6）：679-698
na Anti⁃Cancer Association（CACA）. Chinese guidelines ［27］CHICKLORE S，GOH V，SIDDIQUE M，et al. Quantify⁃
18
on response assessment and minimal residual disease ing tumour heterogeneity in F⁃FDG PET/CT imaging by
monitoring in multiple myeloma（2024）［J］. Chin J Hema⁃ texture analysis［J］. Eur J Nucl Med Mol Imaging，2013，
tol，2024，45（12）：1065-1070 40（1）：133-140
［16］KUMAR S，PAIVA B，ANDERSON K C，et al. Interna⁃ ［28］JOHN M，HELAL M，DUELL J，et al. Spatial transcrip⁃
tional Myeloma Working Group consensus criteria for re⁃ tomics reveals profound subclonal heterogeneity and T ⁃
sponse and minimal residual disease assessment in multi⁃ cell dysfunction in extramedullary myeloma［J］. Blood，
ple myeloma［J］. Lancet Oncol，2016，17（8）：e328- 2024，144（20）：2121-2135
e346 ［29］SEGALL G，DELBEKE D，STABIN M G，et al. SNM prac⁃
18
［17］ZAMAGNI E，PATRIARCA F，NANNI C，et al. Prognos⁃ tice guideline for sodium F⁃fluoride PET/CT bone scans
18
tic relevance of F⁃ FDG PET/CT in newly diagnosed mul⁃ 1.0［J］. J Nucl Med，2010，51（11）：1813-1820
18
tiple myeloma patients treated with up ⁃ front autologous ［30］BEHESHTI M，MOTTAGHY F M，PAYCHA F，et al. F⁃
transplantation［J］. Blood，2011，118（23）：5989-5995 NaF PET/CT：EANM procedure guidelines for bone imag⁃
［18］SACHPEKIDIS C，ENQVIST O，ULEN J，et al. Artificial ing［J］. Eur J Nucl Med Mol Imaging，2015，42（11）：
intelligence ⁃ based，volumetric assessment of the bone 1767-1777
18
marrow metabolic activity in F ⁃ FDG PET/CT predicts ［31］MINAMIMOTO R，MOSCI C，JAMALI M，et al. Semiquan⁃
18
survival in multiple myeloma［J］. Eur J Nucl Med Mol Im⁃ titative analysis of the biodistribution of the combined F⁃
18
aging，2024，51（8）：2293-2307 NaF and F⁃FDG administration for PET/CT imaging［J］.
［19］PELLEGRINO S，ORIGLIA D，DI DONNA E，et al. Coef⁃ J Nucl Med，2015，56（5）：688-694
18
ficient of variation and texture analysis of F⁃FDG PET/ ［32］SACHPEKIDIS C，GOLDSCHMIDT H，HOSE D，et al.
18
CT images for the prediction of outcome in patients with PET/CT studies of multiple myeloma using F⁃FDG and
multiple myeloma［J］. Ann Hematol，2024，103（9）： 18 F⁃NaF：comparison of distribution patterns and tracers’
3713-3721 pharmacokinetics［J］. Eur J Nucl Med Mol Imaging，
［20］BLADE J，BEKSAC M，CAERS J，et al. Extramedullary 2014，41（7）：1343-1353
disease in multiple myeloma：a systematic literature re⁃ ［33］SACHPEKIDIS C，HILLENGASS J，GOLDSCHMIDT H，
18
view［J］. Blood Cancer J，2022，12（3）：45 et al. Quantitative analysis of F ⁃ NaF dynamic PET/CT
［21］LI J，ZHANG X，QIN C，et al. A prognostication system cannot differentiate malignant from benign lesions in mul⁃
based on clinical parameters and［（18）F］⁃FDG PET/CT tiple myeloma［J］. Am J Nucl Med Mol Imaging，2017，7
in patients with newly diagnosed multiple myeloma［J］. （4）：148-156
Eur J Nucl Med Mol Imaging，2023，50（6）：1665-1670 ［34］AK I，ONNER H，AKAY O M. Is there any complimentary
18
18
［22］ZHONG H，HUANG D，WU J，et al. F ⁃ FDG PET/CT role of F⁃ NaF PET/CT in detecting of osseous involve⁃
based radiomics features improve prediction of prognosis： ment of multiple myeloma? A comparative study for F⁃
18
18
multiple machine learning algorithms and multimodality FDG PET/CT and F⁃ FDG NaF PET/CT［J］. Ann Hema⁃
applications for multiple myeloma［J］. BMC Med Imag⁃ tol，2015，94（9）：1567-1575
ing，2023，23（1）：87 ［35］NAKUZ T S，MILLINGER F P，EL ⁃ RABADI K，et al.
［23］ZAMAGNI E，NANNI C，DOZZA L，et al. Standardization Characterization of bone lesions in myeloma before and
18
18
18
of F ⁃ FDG ⁃ PET/CT according to deauville criteria for during anticancer therapy using F⁃FDG⁃PET/CT and F⁃
metabolic complete response definition in newly diag⁃ NaF⁃PET/CT［J］. Anticancer Res，2019，39（4）：1943-
nosed multiple myeloma［J］. J Clin Oncol，2021，39（2）： 1952
116-125 ［36］SACHPEKIDIS C，HILLENGASS J，GOLDSCHMIDT H，
［24］KADDOURA M，DINGLI D，BUADI F K，et al. Prognostic et al. Treatment response evaluation with F⁃FDG PET/CT
18
18
impact of posttransplant FDG PET/CT scan in multiple and F⁃NaF PET/CT in multiple myeloma patients under⁃
myeloma［J］. Blood Adv，2021，5（13）：2753-2759 going high⁃dose chemotherapy and autologous stem cell
［25］XU L，WANG X，PAN X，et al. Education level as a pre⁃ transplantation［J］. Eur J Nucl Med Mol Imaging，2017，
dictor of survival in patients with multiple myeloma［J］. 44（1）：50-62
BMC Cancer，2020，20（1）：737 ［37］ZIRAKCHIAN Z M，OSTERGAARD B，RAYNOR W Y，